

Hong Kong Exchange s and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
翰思艾泰生物醫藥科技（武漢）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3378)

**PROPOSED AMENDMENTS TO
THE ARTICLES OF ASSOCIATION**

The announcement is made by Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (the **“Company”**) pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the **“Listing Rules”**).

Considering the actual circumstances of the Company, the board of directors (the **“Board”**) proposes to adjust the business scope of the Company and make certain

amendments to the Company’s articles of association (the “**Articles of Association**”). Details of the proposed amendments are as follows:

| Original Articles | Revised Articles |
|---|---|
| <p>Article 14</p> <p>Registered in accordance with the law, the business scope of the Company includes: General operations: Medical research and experimental development (excluding human stem cell research, gene diagnosis, therapeutic technology development and application); technical services, technical development, technical consultation, technical exchange, technical transfer and technical promotion; production and sales of Class I medical devices; fermentation process optimization technology research and development. (Except for licensed operations, the company may independently engage in projects not prohibited or restricted by laws and regulations.) Licensed operations: Pharmaceutical production, retail sales, contract manufacturing of pharmaceuticals, and production of Class II medical devices. (Operations requiring legal approval must obtain authorization from relevant authorities, with specific business activities subject to official approval documents or licensing credentials.)</p> | <p>Article 14</p> <p>Registered in accordance with the law, the business scope of the Company includes: General operations: Medical research and experimental development (excluding human stem cell research, gene diagnosis, therapeutic technology development and application), technical services, technical development, technical consultation, technical exchange, technical transfer and technical promotion; production and sales of Class I medical devices; fermentation process optimization technology R&D. (Except for licensed operations, the company may independently conduct business activities not prohibited or restricted by laws and regulations.) Licensed operations: Pharmaceutical production, retail sales, contract manufacturing of pharmaceuticals, and production of Class II medical devices. (Operations requiring approval must obtain authorization from relevant authorities, with specific business activities subject to official approval documents or licensing certificates.)</p> <p><u>Non-residential real estate leasing; conference and exhibition services (international exhibitions require prior approval from relevant authorities). (Except for legally mandated licensed projects, the company may independently conduct business activities based on its business license.)</u></p> |

Save for the above amendments to the Articles of Association, other provisions of the Articles of Association remain unchanged. The English version of the above amendments to the Articles of Association is an unofficial translation of its Chinese version. In case of any discrepancies, the Chinese version shall prevail.

The proposed amendments to the Articles of Association are subject to the approval of the shareholders of the Company by way of a special resolution at the forthcoming 2025 annual general meeting (the “AGM”) and shall take effect on the date the relevant resolution is approved at the AGM. A circular containing details of the above-mentioned proposed amendments to the Articles of Association and the notice of the AGM will be despatched to the shareholders of the Company who request the printed copies in due course.

By Order of the Board
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Dr. ZHANG Faming
Chairman and Executive Director

Hong Kong, March 27, 2026

As at the date of this announcement, the Board comprises (i) Dr. Zhang Faming, Dr. Henry Qixiang Li, Mr. Liu Min and Ms. Xiao Jieyu as executive Directors; (ii) Dr. Li Jian as a non-executive Director; and (iii) Dr. Bi Honggang, Mr. Chen Qifeng, Mr. Wong Sai Hung and Dr. Zhang Qionguang as independent non-executive Directors.